US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.54

+0.11220.39%

Volume:421

Turnover:12.01K

Market Cap:2.57M

PE:- -

High:28.54

Open:28.54

Low:28.54

Close:28.43

52wk High:28.93

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.39

T/O Rate:0.47%

Dividend:0.92

Dividend Rate:3.22%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

Hutchmed initiates Phase Ia part of trial of HMPL-A830

EBR Systems advances FDA approval process for new WiSE manufacturing site

GT Biopharma Regains Nasdaq Minimum Bid Compliance

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

ITC Properties (00199) Establishes AI Infrastructure Business as Separate Reportable Segment

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

Wave Life Sciences initiates Phase 2a combination trial of WVE-007

VOOLT boosts deeptech portfolio with discounted stake in cancer vaccine developer Vaxican

Arterra Bioscience Secures €2 Million Backing for NEX-BIO Biotech Expansion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NVIB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.54,"timestamp":1790882623792,"preClose":28.4278,"halted":0,"volume":421,"delay":0,"changeRate":0.003946840768543392,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0.1122,"latestTime":"10-01 15:27:07 EDT","open":28.54,"high":28.54,"low":28.54,"amount":12014.290026,"amplitude":0,"askPrice":28.79,"askSize":100,"bidPrice":28.72,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.4278,"nav":28.36,"aum":2552427.21,"dividendRate":0.032172,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.61,"preClose":28.4278,"latestTime":"16:10 EDT","volume":6,"amount":170.5668,"timestamp":1790799005215,"change":0.1822,"changeRate":0.006409,"amplitude":0},"volumeRatio":0.388736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.388736,"shares":90001,"dividePrice":0.9182,"high":28.54,"amplitude":0,"preClose":28.4278,"low":28.54,"week52Low":24.54,"pbRate":"--","week52High":28.93,"institutionHeld":0,"latestPrice":28.54,"eps":0,"divideRate":0.032172,"volume":421,"delay":0,"ttmEps":0,"open":28.54,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":27.9349,"twentyDayClose":27.8834},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","LU2324357040.USD","BMED","MRNX","GNMX","BK4584","LFSC","IEIH","XLVX","BK4559","TEVA","RSPH","BK4596","MEDI","MRNY","BK4557","BK4588","BBP","GDOC","BK4585","IDNA","PINK","BK4007","SYNB","NVIB","LU1983299246.USD","LABU","TECB","BK4566","PSCH","IYH","TBXU","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670204232","title":"Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670204232","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670204232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:10","pubTimestamp":1790597436,"startTime":"0","endTime":"0","summary":"TransCode Therapeutics (RNAZ) announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic can...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-reports-updated-results-from-phase-1a-ttx-mc138-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-reports-updated-results-from-phase-1a-ttx-mc138-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","IDNA","LENZ","BK4007","MEDX","HYLG","GDOC","RNAZ","BK4139","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670523240","title":"Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2670523240","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670523240?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"Initial data expected in the first half of 2027LEXINGTON, Mass., Sept.  28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focus","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369820/0/en/keros-therapeutics-announces-the-first-patient-dosing-in-the-phase-2-clinical-trial-evaluating-rinvatercept-in-dmd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","HYLG","GDOC","IDNA","LENZ","NVIB","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670324162","title":"4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME","url":"https://stock-news.laohu8.com/highlight/detail?id=2670324162","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670324162?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet needFirst patients have been enrolled in 4SIGHT global Phase 3 trial (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369825/0/en/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-indication-with-initiation-of-4sight-in-dme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMHX","GAMR","SOXX","NVIB","AMDY","AMDG","SOXY","CST","TEK","AMD","AMDW","AMDU","SAMD0main","AMYY","AIQ","AMDD","ILDR","TTEQ","LU0979878070.USD","MEDX","BAI","USXF","GDOC","FAI","IE00BMPRXN33.USD","QQQA","CHAT","CNAV","PSI","IDNA","ARTY","LU1852331112.SGD","WISE","XNTK","WUGI","AMDL","CHPS","AIS","IETC","AMUU","AMDS","LEGR","BK4534","HYLG","FTXL","AMDC","LU2108987350.USD","DAMD","TRFK","SMH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234567","title":"U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234567?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595000,"startTime":"0","endTime":"0","summary":"NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN rapamycin has the potential to become the first FDA-ap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369784/0/en/u-s-food-and-drug-administration-awards-additional-funding-for-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","LABU","NVIB","BMED","HYLG","GDOC","BK4588","BK4585","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670313732","title":"Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2670313732","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670313732?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593200,"startTime":"0","endTime":"0","summary":"– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept.  28, 2026 (GLOBE NEWSWIRE) -- Arvi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369737/0/en/arvinas-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-arv-6723-the-company-s-first-immuno-oncology-candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","GDOC","MEDX","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670313352","title":"Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2670313352","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670313352?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593200,"startTime":"0","endTime":"0","summary":"–Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits –Independent Cleveland Clinic cardio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369741/0/en/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-analysis-of-annamycin-in-frontiers-in-cardiovascular-medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","BK4082","GDOC","BMED","IDNA","NVIB","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670605236","title":"MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2670605236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670605236?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:15","pubTimestamp":1790590507,"startTime":"0","endTime":"0","summary":"MediciNova (MNOV) announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyce...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MNOV","BBC","GDOC","NVIB","PSIL","HYLG","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","MRNX","BMED","GNMX","LFSC","IEIH","XLVX","RSPH","MEDI","MRNY","BK4588","BBP","GDOC","BK4585","IDNA","PINK","TBPH","BK4007","SYNB","NVIB","LABU","TECB","PSCH","IYH","TBXU","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402037","title":"Hutchmed initiates Phase Ia part of trial of HMPL-A830","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402037?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:45","pubTimestamp":1790556321,"startTime":"0","endTime":"0","summary":"Hutchmed (HCM) announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hutchmed-initiates-phase-ia-part-of-trial-of-hmpl-a830-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hutchmed-initiates-phase-ia-part-of-trial-of-hmpl-a830-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4007","HCM","HYLG","BK4585","GDOC","IDNA","BK4531","BK4588","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","EES","IDNA","NVIB","SYNB","XLVX","BBP","PSCH","RSPH","GDOC","PINK","FRTY","GNMX","BK4588","MRNY","IEIH","TECB","BMED","IYH","LABU","MEDI","IBB","BK4585","MRNX","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670553422","title":"GT Biopharma Regains Nasdaq Minimum Bid Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2670553422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670553422?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:54","pubTimestamp":1790369640,"startTime":"0","endTime":"0","summary":"GT Biopharma ( ($GTBP) ) has provided an announcement. GT Biopharma, Inc., a Nasdaq-listed biotech company, had fallen out of compliance with the e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gt-biopharma-regains-nasdaq-minimum-bid-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gt-biopharma-regains-nasdaq-minimum-bid-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","XBIX","BK4588","NVIB","LCLG","GT","BK4119","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669934134","title":"Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2669934134","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669934134?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:00","pubTimestamp":1790251200,"startTime":"0","endTime":"0","summary":"Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of EtripamilMONTREAL and CHARLOTTE, N.C., Sept.  24, 2026 (GLOBE NEWSWIRE) -- Milestone Phar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368250/0/en/milestone-pharmaceuticals-enrolls-first-canadian-study-participant-in-revera-301-phase-3-pivotal-trial-evaluating-etripamil-nasal-spray-for-afib-rvr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","MEDX","ECG","BK4588","BK4585","VR","NVIB","LU1559883803.SGD","LABU","HYLG","GDOC","IDNA","AV","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461761","title":"MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461761","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461761?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:10","pubTimestamp":1790244648,"startTime":"0","endTime":"0","summary":"MediciNova (MNOV) announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicinova-completes-lplv-in-phase-2b-3-clinical-trial-evaluating-mn-166-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicinova-completes-lplv-in-phase-2b-3-clinical-trial-evaluating-mn-166-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","BK4139","MEDX","NVIB","HYLG","MNOV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461514","title":"MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461514","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461514?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244000,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368112/7767/en/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-portion-of-the-phase-2b-3-combat-als-trial-of-mn-166-ibudilast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","MEDX","IE00B3S45H60.SGD","BK4588","BMED","CAFS","BK4581","LU0006306889.USD","LU0106831901.USD","LU0795875086.SGD","LU0320765646.SGD","LU1720051017.SGD","LU1988902786.USD","LU0557290698.USD","LU1363072403.SGD","LU1989772840.SGD","GDOC","LU2264538146.SGD","EMA","LU0106261372.USD","LU0528227936.USD","LU1732800096.USD","LU0314104364.USD","ARDS","LU1720051108.HKD","KBWB","MNOV","LU0971096721.USD","NVIB","LU2089283258.USD","LU1244550221.USD","HYLG","BK4516","LU0053666078.USD","IE00BKVL7J92.USD","LU0882574139.USD","LU1162221912.USD","BK4504","LU0158827781.USD","LU0210528500.USD","LU0225283273.USD","LU2023251221.USD","LU2111349929.HKD","LU2133065610.SGD","LU2357305700.SGD","LU1244550577.SGD","LU0795875169.SGD","LU0234570918.USD","IAI","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166586645","title":"ITC Properties (00199) Establishes AI Infrastructure Business as Separate Reportable Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=1166586645","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166586645?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:10","pubTimestamp":1790241040,"startTime":"0","endTime":"0","summary":"ITC Properties (00199) has announced that in September 2026, the company officially changed its name to ITC Neocloud Group Limited.With the development of the group's artificial intelligence (AI)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRAI","WDAI","QQJG","XQQI","USMD","MQQQ","AIVC","AIS","WDCC","AVGC","SMCX","AMZD","ORCU","SPRX","ORAC","GTEK","AIQD","ORCS","DARP","AMZO","AVGU","QQQG","BK1240","AXTL","AGIQ","BAY","FDIF","AZYY","AMZU","AMZG","AMZP","AXTC","AVGW","AMZY","AIPI","AMAA","AVGG","QBIG","SMCL","AXTQ","ORCX","CRTC","XLKI","AVGX","00199","AXTX","THMZ","BTHM","QMNV","QXQ","AMZW","SMYY","IVEP","SMCC","SMCZ","TEKY","DAT","INVN","NTAL","SMCY","AVL","ORCZ","AVS","RSPT","TIME","TTXU","AMZZ","GPTY","TEK","TTEQ","EPAI","WDCX","FRWD","QNXT","AXTU","ALAI","FXL","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","BK4139","LABU","BK4588","NVIB","LFSC","MRNX","BK4585","XLVX","MEDI","GNMX","BBP","IBB","GDOC","FRTY","IYH","TBXU","IEIH","IDNA","RSPH","PSCH","PINK","SYNB","MESO","TECB","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882944","title":"Wave Life Sciences initiates Phase 2a combination trial of WVE-007","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882944?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:35","pubTimestamp":1790163326,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combinatio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HYLG","IDNA","MEDX","WVE","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110098","title":"VOOLT boosts deeptech portfolio with discounted stake in cancer vaccine developer Vaxican","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110098","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110098?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:47","pubTimestamp":1790160467,"startTime":"0","endTime":"0","summary":"An announcement from VOOLT Spolka Akcyjna ( ($PL:VLT) ) is now available. VOOLT S.A. has increased its stake in Polish biotech spin-off Vaxican sp....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-discounted-stake-in-cancer-vaccine-developer-vaxican?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-discounted-stake-in-cancer-vaccine-developer-vaxican?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","EVNT","VLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669556124","title":"Arterra Bioscience Secures €2 Million Backing for NEX-BIO Biotech Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2669556124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669556124?lang=en_us&edition=fundamental","pubTime":"2026-09-23 03:02","pubTimestamp":1790103749,"startTime":"0","endTime":"0","summary":"The latest update is out from Arterra Bioscience SpA ( ($IT:ARBS) ). Arterra Bioscience S.p.A., a Naples-based green biotech group listed on Eurone...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arterra-bioscience-secures-e2-million-backing-for-nex-bio-biotech-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arterra-bioscience-secures-e2-million-backing-for-nex-bio-biotech-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IOBT","BK4585","VGT","BK4139","BK4581","BK4588","XBIX","NVIB","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}